ArticleBMC immunology2025
Exploration of biomarkers for predicting the prognosis of patients with diffuse large B-cell lymphoma by machine-learning analysis.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid Metabolism Reprogramming in Diffuse Large B-Cell Lymphoma (DLBCL): Mechanisms and Treatment Strategies.Cancers · 2026Review
- Mortality Prediction in Diffuse Large B-Cell Lymphoma Using Supervised Machine Learning Models-A Retrospective Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAs one distinct origin of hematological malignancies, diffuse large B-cell lymphoma (DLBCL) has caused a major public health problem. However, the molecular mechanisms that underlie this association have not been clearly elucidated. To improve this situation, it is urgent to explore disease-specific diagnostic biomarkers and mechanisms.
methodsThree microarray datasets (GSE25638, GSE12195 and GSE12453) were downloaded from the Gene Expression Omnibus (GEO) database. The key genes in DLBCL patients were screened by differentially expression gene (DEG) and weighted gene co-expression network analysis (WGCNA). Functional enrichment analysis and protein-protein interaction (PPI) network construction were employed to reveal DLBCL-related pathogenic molecules and underlying mechanisms. Candidate biomarkers were screened using random forest (RF) analysis. A diagnostic nomogram and Kaplan-Meier (KM) survival analysis were constructed to predict the risk of patients. Single-sample gene set enrichment analysis (ssGSEA) was used for exploring immune cell infiltration in lymphoma. The validation of the hub genes expressions was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) tests.
resultsA total of 95 key genes were acquired from three datasets of DLBCL patients by DEG analysis and WGCNA. DEGs were significantly enriched in pathways associated with inflammatory response, biological process involved in interspecies interaction between organisms, C-X-C chemokine receptor binding as well as chemokine activity. This was determined by Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. Moreover, four hub genes (CXCL9, CCL18, C1QA and CTSC) were significantly screened from the three datasets using RF algorithms. They were closely correlated with the overall survival of DLBCL patients. The dysregulated infiltration of immune cells, including natural killer (NK) cells and T cells, were positively linked to the expression levels of the four hub genes. The receiver operating characteristic (ROC) results were promising via the construction of a nomogram model. Additionally, the increased expression of the four key genes was further verified in DLBCL patients.
conclusionFour crucial hub genes (CXCL9, CCL18, C1QA and CTSC) that could predict the risk of DLBCL were systematically identified. In particular, CXCL9 may be the most important potential biomarker for the progression of DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.